Table 2. Outcome Characteristics of European and North American Trials [4-20].

	Group	Index hospital revascularization (%)	Total revascularized patients (%)	Total deaths (%)	Cardiac deaths (%)	Repeat MI during follow-up (%)	Rehospitalization due to ischemic heart disease (%)	CABG(%)
European trials
FRISC [4]	REV	76	82	38.7	14.3	37.2	-	-
	SLR	14	58	39	16	45	-	-
RITA-3 [5]	REV	55	61	25.1	15.1	-	-	21
	SLR	10	38	25.4	16.1	-	-	4
ITALIAN ELDERLY ACS [15]	REV	56	58	12.3	10.4	7.1	16	7
	SLR	23	31	13.8	10.7	10.7	21	2.5
ICTUS [6]	REV	-	83	26.7	17.6	18.9	-	-
	SLR	-	61	23.7	15.2	14.9	-	-
ISAR COOL [16]	REV	78.3	-	0	-	6	-	7.9
	SLR	72	-	1.4	-	10.1	-	7.7
LIPSIA NSTEMI [11]	REV	84	-	5.2	-	2.2	28	10
	SLR	70	-	6.5	-	1	9	13
OPTIMA [19]	REV	-	100	1	-	3	18	-
	SLR	-	99	0	-	4	14	-
TRUCS [10]	REV	78	100	3.9	-	3.9	13	33
	SLR	38	61	12.5	-	4.2	17	18
VINO [20]	REV	-	73	3.1	-	3.1	2	35
	SLR	-	39	13.4	-	14.9	2	30
ABOARD [12]	REV	-	80.1	2.9	-	9.1	12	11
	SLR	-	69.5	1.1	-	4.5	18.6	11.3
ELISA [13]	REV	61	-	3	-	7	-	14
	SLR	58	-	5	-	6	-	19
North American trials (Canada/US)
MATE [7]	REV	58	72	11	-	6	23	18
	SLR	37	60	6	-	2	22	11
OASIS 5 [9]	REV	57.7	64	8.8	-	12.9	-	16
	SLR	30.4	51	2.2	-	13.3	-	12
TACTUS TIMI 18 [17]	REV	51	64	3.3	-	4.8	11	22
	SLR	36	45	3.5	-	6.9	13.7	16
TIMACS [14]	REV	74.4	93.1	4.8	-	4.8	1	14.8
	SLR	68.7	77.2	5.9	-	5.7	3.3	13.6
TIMI IIIB [18]	REV	6	64	8.8	-	16.3	26	30
	SLR	19	58	9.9	-	15.4	33	30
VANQUISH [8]	REV	44	-	17.3	-	15.6	-	20
	SLR	33	-	13	-	17.4	-	19